Clinical Trial Update: A Study of IBI362 in Participants With Obesity or Overweight [Phase 3]

View source ↗

Summary

A Phase 3 study of IBI-362 in participants with obesity or overweight has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• IBI-362

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Obesity Or Overweight | Phase 3 | Status: COMPLETED